MVP Act

HR 7871 (MVP Act) updates Medicaid drug rebate rules to allow manufacturers to report multiple "best price points" for drugs sold under outcome-based payment arrangements, requiring these arrangements to be offered to all states. It clarifies how average manufacturer price is calculated for such drugs and exempts certain outcome-linked payments from anti-kickback laws. The bill also mandates a GAO study to assess whether these arrangements improve patient access, lower costs, and reduce disparities in drug coverage. This affects Medicaid programs nationwide, drug manufacturers, and patients receiving covered outpatient drugs under Medicaid.